Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001

Bernhard, Jürg; Dietrich, Daniel; Scheithauer, Werner; Gerber, Daniela; Bodoky, György; Ruhstaller, Thomas; Glimelius, Bengt; Bajetta, Emilio; Schüller, Johannes; Saletti, Piercarlo; Bauer, Jean; Figer, Arie; Pestalozzi, Bernhard C; Köhne, Claus-Henning; Mingrone, Walter; Stemmer, Salomon M; Tàmas, Karin; Kornek, Gabriela V; Koeberle, Dieter; Herrmann, Richard; ... (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology, 26(22), pp. 3695-701. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2007.15.6240

Full text not available from this repository. (Request a copy)

To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bernhard, Jürg

ISSN:

0732-183X

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:24

Last Modified:

17 Mar 2015 22:51

Publisher DOI:

10.1200/JCO.2007.15.6240

PubMed ID:

18669454

Web of Science ID:

000258052100009

URI:

https://boris.unibe.ch/id/eprint/37814 (FactScience: 211447)

Actions (login required)

Edit item Edit item
Provide Feedback